Celebrex 1999 Study Showing Cardiovascular Risk Was Disclosed, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The study was presented at a scientific meeting in 2000 and submitted to FDA in 2001, Pfizer says. The cardiovascular events seen in the Alzheimer's study, highlighted in a recent Public Citizen letter to FDA, do not indicate a danger from Celebrex because of the underlying cardiovascular risk profile of the celecoxib arm, Pfizer says.
You may also be interested in...
Pfizer's Celebrex Showed Cardiovascular Risk In 1999 Alzheimer's Study
A study of celecoxib in Alzheimer's disease patients showed a statistically significant increase in cardiovascular events versus placebo. The study data are posted on PhRMA's clinicalstudyresults.org website, but Public Citizen alleges Pfizer recently revised the posting and questions when the data were submitted to FDA.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said